Did you know that any changes you make to the structure of your business can have an impact on your ability to continue with ...

Discover why Southern Company offers 12% upside and a 3.5% yield. Explore Q3 results, growth from data centers, and dividend ...

Monday was quite the day for biotech companies developing the next generation of obesity drugs. One of them, Structure ...

AI companies' fundamentals are positive. But strong fundamentals don't always justify high valuations. The trick is to figure ...

Sinopec Shanghai Petrochemical Co ( ($HK:0338) ) has issued an update. Sinopec Shanghai Petrochemical Company Limited has ...

If your current approach to budgeting feels rigid, outdated or disconnected from your goals, it’s time to reimagine it.

Johnson & Johnson MedTech (NYSE:JNJ) is enacting an organizational restructuring, changing the way its business units operate ...

Synergy Business Brokers reports that selling a profitable business requires careful planning, organized financials, and ...

Structure Therapeutics (GPCR) announced the pricing of its upsized underwritten public offering, to generate gross proceeds of approximately $650 million. The company's offering was upsized from a ...

Structure Therapeutics said on Monday its obesity pill showed weight loss of up to 11.3% after 36 weeks of treatment in a mid-stage study, driving the company's shares more than 140% higher.

You cannot create institutional intelligence when knowledge lives in silos. You cannot compound learning when every insight ...

Structure Therapeutics is developing a daily GLP-1 receptor pill called aleniglipron, that just showed positive results from a Phase 2 trial.